LI
ZYNE

Leap Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Leap Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46,084
Closed -$348K – 635
2019
Q3 		$348K Buy
+46,084
New +$519K 0.17% 207

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Leap Investments's ZYNE Position: Q4 2019 in Review

Leap Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 46,084 shares — an estimated $348K sold.

Leap Investments first reported a position in ZYNE in Q3 2019 and held it in 1 quarter. The position peaked at $348K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

  • Leap Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 46,084 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $348K.
  • Leap Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 1 quarter.
  • Leap Investments's Zynerba Pharmaceuticals, Inc position peaked at $348K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.